Last updated: 2026-09-09 19:19:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
ANI Pharmaceuticals, Inc. (ANIP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $70.09, with a market capitalisation of $1.64B and a P/E ratio of 16.20. Over the past 52 weeks, its price has ranged from $70.06 to $99.50. This page covers its latest market performance, valuation, price trends and company information.
$1.64B | |
$70.63 | |
$99.50 | |
$5.99 | |
$70.23 | |
147.97K | |
341.45K | |
16.20 | |
$99.50 | |
$70.06 | |
0.02% | |
-- |
ANI Pharmaceuticals, Inc. (ANIP) is currently trading at $70.09 as of 2026-09-09 19:02:03, down 0.19% ($0.14) from the previous close of $70.23
During today's regular trading session, ANIP has traded between $5.99 and $99.50, with a trading volume of 147.97K shares. The current price is near the upper end of today's range.
Over the past seven days, ANI Pharmaceuticals, Inc. (ANIP) moved from $72.83 to $70.09, representing a decline of 3.76% ($2.74).
The stock traded between $70.06 and $74.99 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 340.06 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.1%
ANIP is currently trading at $70.09, placing it 0.1% of the way from its 52-week low of $70.06 to its 52-week high of $99.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 970 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ANI Pharmaceuticals, Inc. (ANIP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.